US EditionNovo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%
Novo Nordisk will reduce list prices for Wegovy by 50% and Ozempic by 35% to $675 monthly starting Jan. 1, 2027, aiming to improve insured patients' access.
- Novo Nordisk announced a cut to U.S. list prices for Ozempic, Rybelsus and Wegovy to $675 for a one-month supply, effective Jan. 1, 2027.
- On Feb. 23, Novo released head-to-head trial results showing CagriSema produced 23% weight loss over 84 weeks versus 25.5% for tirzepatide, and Novo Nordisk shares fell 16% on Monday.
- The company says the list-price change targets insurance-based cost-sharing, with Miller stating, 'We think this addresses and responds to repeated call for lower list prices...'
- Cash-Paying customers, however, will largely see no change since Wegovy's list price remains $1,349 and some direct-purchase cash prices were already cut to $349; Novo recently sued telehealth company Hims & Hers, with John Kuckelman, Novo Nordisk group general counsel, warning others.
- About 7 in 10 people who've taken GLP-1 medications said cost influenced their treatment decisions, and Navitus Health Solutions found 1 in 4 paid more than $250 per fill; Sharon Faust said, 'Difficult tradeoffs exist for patients and plan sponsors alike.
106 Articles
106 Articles
Pioneer Press
Ozempic, Wegovy list prices to be slashed by up to 50%
Weight loss drugmaker Novo Nordisk will cut the list prices of Ozempic and Wegovy by up to 50% beginning in 2027, the company announced this week. Wegovy currently carries a list price of $1,349 per month, while Ozempic is listed at $1,028 for a one-month supply. Both drugs will be listed at $675 per month beginning on Jan. 1, 2027, “representing reductions of approximately 50% and 35% for Wegovy and Ozempic, respectively,” according to Novo Nor…
Novo to Slash GLP-1 Prices
Photo: Josh Morgan ~ USA TODAY NETWORK DETROIT, MICH. ~ Starting in 2027, Novo Nordisk will cut the costs of monthly supplies of three GLP-1’s that help with diabetes and weight-loss. A four-week supply of Ozempic, Wegovy, and Rybelsus will all be priced at $675 beginning on Jan. 1 next year due to competition from Eli Lilly. Customers will save hundreds with these cuts, as the current price of Wegovy is more than double the new rate. These pri…
Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low
After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low. As a result, Reddit sentiment has followed along with this downward shift, sliding from a quarterly average of 56 to a weekly average of 43 ... Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low
Anti-Obesity Treatments: Novo Nordisk, Under Pressure in the United States, Counter-Attack on Prices
A manufacturer of Wegovy Obesity Treatment and Ozempic Antidiabetic, the Danish laboratory is losing speed in the United States, its main market, where it faces competition from the American Eli Lilly.
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
